Abeterno Overview
- Founded
-
2011
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Liquidation
Abeterno General Information
Description
Developer of research tools for cell separation and live cell imaging. The company's research tools have developed novel cell isolation technology that makes use of magnetic nanoparticles to purify live cells using intracellular proteins.
Contact Information
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
- Cambridge
- England, United Kingdom
Abeterno Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Bankruptcy: Liquidation | 01-Feb-2017 | Completed | Bankruptcy: Liquidation | |||
| 1. Seed Round | Completed | Startup |
Abeterno Patents
Abeterno Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201417809-D0 | Nanoparticles | Inactive | 08-Oct-2014 | ||
| GB-201207177-D0 | Intracellular cell selection | Inactive | 24-Apr-2012 | ||
| GB-201115847-D0 | Cell isolation | Inactive | 14-Sep-2011 |
Abeterno Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Rosalind Codrington Ph.D | Founder & Chief Scientific Officer | ||
| Michael McLean Ph.D | Board Member & Chief Executive Officer |
Abeterno Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Griffitths | Abeterno | Board of Director | 000 0000 |
| Linda Cammish Ph.D | Abeterno | Board of Director | 000 0000 |
| Michael McLean Ph.D | Self | Board Member & Chief Executive Officer | 000 0000 |
Abeterno Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
